Clinical Trial Update: Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump [Phase 3]

View source ↗

Summary

Phase 3 safety study of intrathecal baclofen injection (3 mg/mL) using a programmable pump completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spasticity

Drugs mentioned

• BACLOFEN (Baclofen)

Snippet

Sponsor: Piramal Critical Care, Ltd. | Conditions: Severe Spasticity | Phase 3 | Status: COMPLETED